Development of Hybrid Shear-thinning Hydrogels as an Injectable Delivery Platform for Repair of Chronic Diabetic Skin Wounds
Date
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
In the inflammatory phase of wound healing, reactive oxygen species (ROS) are produced to fight microorganisms, prevent infection, and promote immune cells. However, hyperglycemia in diabetic wounds impairs this function by sustaining oxidative stress, preventing resolution of inflammation, and blocking the transition to later stages of wound healing. A hybrid hydrogel system was developed as a bioresorbable and injectable therapeutic delivery platform for controlled delivery of molecular and biologic therapeutic cargos to address limitations of treatments currently available for resolving severely-compromised diabetic skin wounds. The hydrogel integrates synthetic nanoparticles with a natural biopolymer through physical crosslinking facilitated by guest-host complexation of adamantane (AD) and beta-cyclodextrin (β-CD), to produce a hydrogel that can serve as an injectable delivery platform for small molecule PHD2 inhibitors and urine-derived stem cells (USCs) or their extracellular vesicles (USC-EVs) but can also serve as a biodegradable reservoir that provides inherent antioxidant and ROS-responsive behavior. Poly(propylene sulfide) (PPS) was incorporated as the core-forming block of self-assembled nanoparticles displaying AD on their surface, and incorporation of nanoparticles with β-CD grafted-hyaluronic acid produced hybrid hydrogels possessing shear-thinning/self-healing behavior. The impact of polysulfide chemistry on the antioxidant function of hybrid hydrogels was investigated by replacing PPS in the nanoparticles with different polysulfide monomers to yield hydrogels possessing a range of ROS-reactivities. The evaluation of hybrid hydrogels identified polysulfide chemistries which provided sustained release of small molecule PHD2 inhibitors, reduced levels of oxidative stress, possessed potent antioxidant functions, including protecting USCs from cytotoxic ROS, and identified hydrogels that demonstrated promise as an injectable delivery platform for improving outcomes in diabetic skin wounds. Those hydrogels were evaluated for therapeutic delivery of small molecule PHD2 inhibitors and USCs/USC-EVs by more rigorous, diseased wound healing models in diabetic mice and diabetic mini-pigs, which not only provided new knowledge on the activation of broad growth programs through PHD2 inhibition and extracellular vesicle signaling pathways, but also demonstrated clinical potential of hybrid hydrogels as a versatile and unique therapeutic delivery platform for accelerated repair of severely-compromised diabetic skin wounds.